# Jingfeng Biological

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jingfeng-biological

- Industry: Biotechnology
- Headquarters: Qingdao, China
- Total disclosed funding: $10M
- Latest round: Series A (Oct 11, 2021)
- Investors on record: 1

## About

Established in 2020 and based in Qingdao, China, Jingfeng Biological is a biological company that focuses on the research and development of tumor cell therapy products. Dr. Fuli Yu, the company’s founder and CEO, worked in the Human Genome Sequencing Center of the Department of Genetics of Baylor College of Medicine and served as the Chief Information Officer of Berry Gene.

The company engages in the research and development of tumor cell therapy products. Its main products include neoantigen-driven TIL, single-cell multi-omics TIL scanning, and end-to-end CMC. The company's products are used in the treatment of tumor infiltrating lymphocytes (TIL).

## Funding rounds

- Series A, Oct 11, 2021, $10M — Dalton Venture

## Investors

- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Series A